CA-ELEGEN
Elegen, a leader in DNA manufacturing innovation, today announced a collaboration and licensing agreement with GSK (LSE/NYSE: GSK) to enable its use of Elegen’s proprietary cell-free DNA manufacturing technology in the development of GSK’s vaccines and medicines.
The terms of the agreement include upfront fees and purchase commitments of Elegen’s ENFINIA DNA to support GSK’s development of medicines and vaccines, including RNA vaccines. Elegen is also eligible to receive both near-term milestone payments relating to the development of new product features and a potential equity investment in Elegen by GSK.
Commercially launched in March of last year, ENFINIA DNA delivers NGS-verified, high-complexity, clonal-quality, linear DNA up to 7kb in as fast as seven business days. Unlike conventional synthesis of mRNA from linearized plasmid DNA, Elegen’s DNA is produced entirely cell-free, with the potential to enable a seamless transition from discovery to clinical scale-up under GMP. This technology may save significant time and substantial resources spent iteratively cloning, linearizing and purifying plasmid DNA as well as generating master cell banks. Elegen’s innovation in cell-free DNA manufacturing technology represents a significant leap forward that could power the next generation of mRNA, cell and gene therapies.
This collaboration follows the Early Access Program launched by Elegen in May of last year that offered DNA of longer length and higher complexity to select customers. “Over the past year dozens of customers, including multiple top 10 biopharma, have validated the unprecedented speed, length, accuracy and complexity of our cell-free DNA manufacturing technology,” said Matthew Hill, Ph.D., Elegen founder and CEO. “GSK recognizes the importance of a reliable, turnkey supply of DNA for a variety of applications for which speed, accuracy and quality of DNA synthesis are essential. This collaboration will expand our offering to include the clinical production of genetic medicines potentially including mRNA, cell and viral gene therapies.”
About Elegen
Elegen is bringing unique insights and technical innovation to create high-quality synthetic DNA faster, catalyzing the next revolution in the life sciences. The company is led by seasoned leaders with decades of experience developing novel and scalable approaches in molecular biology, chemistry and microfluidics. Elegen uses a proprietary microfluidics approach to build longer, higher-quality DNA on a faster timeline for agricultural, chemical, healthcare and pharma industries. Founded in 2017, Elegen is privately held and based in the San Francisco Bay Area. For more information, visit elegenbio.com and connect with us on LinkedIn and X (Twitter).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240124105579/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech and Zscaler Expand Partnership for AI-Powered Security and Network Transformation16.10.2025 20:13:00 CEST | Press release
HCLTech, a leading global technology company, and Zscaler™, a leader in cloud security, announced the expansion of their strategic partnership to provide AI-powered network transformation and enhanced zero-trust security services to enterprises worldwide. Under the new partnership scope, Zscaler's Zero Trust Exchange™ platform has been integrated with HCLTech's Cybersecurity Fusion Center (CSFC) platform. HCLTech’s AI capabilities, including SecOps and Responsible AI guardrails within HCLTech AI Force and AI Foundry are key to this partnership. This collaboration aims to enhance enterprise resilience and achieve business outcomes with a cloud-first, scalable security solution. HCLTech's Universal Managed Detection and Response (UMDR) services now integrate with Zscaler Internet Access™ (ZIA™), Zscaler Private Access™ (ZPA™) and other Zscaler components, providing context-rich threat detection, advanced analytics and faster response powered by AI and automation. Other key highlights of
Beyon Cyber and Haven Sign MoU to Launch Advanced AI-Powered SOC Capabilities in the UK and Worldwide16.10.2025 19:58:00 CEST | Press release
Beyon Cyber, part of the Beyon Group and the fastest growing cyber security company in the Middle East, has signed a Memorandum of Understanding (MoU) with Haven Cyber Technologies, a global cyber security services provider and a Microsoft Solutions Partner, through its UK-based subsidiary ITC Secure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016047852/en/ Beyon Cyber and Haven Sign MoU Under the MoU, Beyon Cyber and Haven will form a strategic partnership to revolutionize cyber security operations through the launch of advanced AI-driven Security Operations Centers (AI SOCs) in the United Kingdom and worldwide. As part of this collaboration, Haven will integrate Beyon Cyber’s cutting-edge AI SOC platform, Orryx AI, into its operations; harnessing the power of smart automation and agentic AI workflows to enhance threat detection, investigation, hunting, intelligence, and response. This partnership will enable both or
Stefanini Honored at ISG Women in Digital Awards EMEA as Natalia Chiritescu Wins Bronze Luminary for AI Leadership16.10.2025 17:23:00 CEST | Press release
Recognition underscores Stefanini’s AI-First strategy and global commitment to accelerating digital transformation through innovation and inclusion. Information Services Group (ISG) has honored Stefanini at the Women in Digital Awards in EMEA, celebrating Natalia Chiritescu. Chiritescu, Digital Solutions Center (DSC) Director for EMEA, NA, & APAC, was awarded “Bronze Luminary” in the AI Champion category recognizing AI adoption and enablement impact. The ISG Women in Digital Awards program, launched in the Americas in 2022, was expanded in 2023 to the Europe, Middle East and Africa (EMEA) and Asia Pacific regions, including India. In 2025, the global program had a total of 536 finalists and winners were announced on September. “The Women in Digital Awards aim to elevate and connect visionary women across the tech landscape. Natalia Chiritescu’s achievement is a testament to the program’s purpose: to foster collaboration, innovation, and diversity, empowering leaders to drive AI-enabled
CyberArk Named a Leader in the 2025 Gartner® Magic Quadrant™ for Privileged Access Management16.10.2025 17:06:00 CEST | Press release
CyberArk is recognized as a Leader for the seventh consecutive time.CyberArk's view is that recognition underscores the company's vision and innovation in the PAM market.CyberArk Identity Security Platform secures all identities with modern privilege controls. CyberArk (NASDAQ: CYBR), the global leader in identity security, today announced it has been named a Leader in the 2025 Gartner® Magic Quadrant™ for Privileged Access Management1. Recognized as a Leader for the seventh consecutive time, CyberArk is positioned furthest in Completeness of Vision which, from the company's standpoint, reflects CyberArk's commitment to defining the future of privilege access management (PAM), where every identity is protected with flexible as-needed access, smart AI-driven privilege controls, and unified security across both cloud and on-premises systems. The report evaluates tools that manage privileged access for both humans and machines. The CyberArk Identity Security Platform enables organizations
HistoSonics Announces Oversubscribed $250 Million Growth Financing16.10.2025 16:00:00 CEST | Press release
With backing from Peter Thiel, K5 Global, Jeff Bezos, and Wellington Management, among others, HistoSonics is positioned to expand globally across new clinical applications HistoSonics, Inc., the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the closing of an oversubscribed $250 million financing led by its new ownership group and included additional investors Thiel Bio and Founders Fund, among others. The financing will support the ongoing commercial expansion of HistoSonics’ Edison System into new global markets, accelerate new clinical indications throughout the body, and strengthen operational capacity for the next phase of growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016119331/en/ HistoSonics Non-Invasive Edison Histotripsy System Image credit: HistoSonics This funding follows the recent $2.25 billion majority stake acquisition of HistoSonics by a consor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom